Renal allograft biopsies with borderline changes: Predictive factors of clinical outcome

American Journal of Transplantation

Volumn 6, Issue 7, 2006, Pages 1725-1730

  Dahan, K ^a   Audard, V ^a   Roudot Thoraval, F ^a   Desvaux, D ^a   Abtahi, M ^a   Mansour, H ^a   Kumal, M ^a   Lang, P ^a   Grimbert, P ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute rejection; Antirejection therapy; Borderline changes

Indexed keywords

CREATININE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BIOPSY; CREATINE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33745367741     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01348.x     Document Type: Article

References (17)

1. Furness PN Kirkpatrick U Taub N Davies DR Solez K. A UK-wide trial of the Banff classification of renal transplant pathology in routine diagnostic practice. Nephrol Dial Transplant 1997 12 : 995 1000.
2. Racusen LC Solez K Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723.
3. Desvaux D Schwarzinger M Pastural M et al. Molecular diagnosis of renal-allograft rejection: Correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation 2004 78 : 647 653.
4. Lipman ML Shen Y Jeffery JR et al. Immune-activation gene expression in clinically stable renal allograft biopsies: Molecular evidence for subclinical rejection. Transplantation 1998 66 : 1673 1681.
5. Meehan SM Siegel CT Aronson AJ et al. The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J Am Soc Nephrol 1999 10 : 1806 1814.
6. Saad R Gritsch HA Shapiro R et al. Clinical significance of renal allograft biopsies with "borderline changes," as defined in the Banff Schema. Transplantation 1997 64 : 992 995.
7. Gaber LW Moore LW Alloway RR et al. Correlation between Banff classification, acute renal rejection scores and reversal of rejection. Kidney Int 1996 49 : 481 487.
8. Gaber LW Schroeder TJ Moore LW Shakouh-Amiri MH Gaber AO. The correlation of Banff scoring with reversibility of first and recurrent rejection episodes. Transplantation 1996 61 : 1711 1715.
9. Schweitzer EJ Drachenberg CB Anderson L et al. Significance of the Banff borderline biopsy. Am J Kidney Dis 1996 28 : 585 588.
10. Morrissey PE Gohh R Shaffer D et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation 1997 63 : 845 848.
11. Perico N Cattaneo D Sayegh MH Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004 364 : 1814 1827.
12. Solez K Axelsen RA Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993 44 : 411 422.
13. Sijpkens YW Doxiadis II Mallat MJ et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003 75 : 204 208.
14. Kaminska D Tyran B Mazanowska O et al. Intragraft mRNA expression of cytokines and growth factors in human kidney allograft biopsies by in situ RT-PCR analysis. Transplant Proc 2005 37 : 767 769.
15. Hribova P Kotsch K Brabcova I Vitko S Volk HD Lacha J. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 2005 37 : 760 763.
16. Graca L Cobbold SP Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002 195 : 1641 1646.
17. Strom TB. Is transplantation tolerable? J Clin Invest 2004 113 : 1681 1683.